[February 08, 2016]

Global Hepatitis Drugs Market Growth of 29.7% CAGR by 2020 - Analysis, Technologies & Forecast Reprot 2016-2020 - Key Vendors: GlaxoSmithKline, Johnson & Johnson, Gilead Sciences - Research and Markets

Research and Markets (http://www.researchandmarkets.com/research/gk9j9x/global_hepatitis) has announced the addition of the "Global Hepatitis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2020" report to their offering.

The global hepatitis drugs market accounted for revenue of $23,222.1 million in 2014, and it is expected to grow with a CAGR of 29.7% during 2015 - 2020. Among the various types, the hepatitis C segment dominated the global hepatitis drugs market, with 76.1% share in 2014.

The restraints associated with the growth of the global hepatitis drugs market include high capital expenditure and stringent regulatory requirements. The growing number of collaboration and partnerships is one of the latest trends observed in the market.

This research offers actual historical market size for 2014, estimate for 2015and forecast for the period 2016 - 2020, of the global hepatitis drugs market in the U.S. dollars.

Global Hepatitis Drugs Market Breakdown:

• By Type - Hepatitis A, Hepatitis B, Hepatitis C, and Others
• By Drugs - Hepatitis B Drugs (Baraclude, Viread, Tyzeka, Hepsera, and Others), and Hepatitis C Drugs (Sovaldi, OLYSIO, Harvoni, Pegasys, PegIntron, Victrelis, and Others)
• By Region - North America, Europe, Asia, and Rest of the World (RoW).

Companies Mentioned:

• Gilead Sciences Inc.
• F. Hoffmann-La Roche Ltd
• Johnson & Johnson
• Merck & Co., Inc.
• GlaxoSmithKline plc
• AbbVie Inc.
• Novartis AG
• Bristol-Myers Squibb Company
• Dynavax Technologies Corporation
• Mitsubishi (News - Alert) Tanabe Pharma Corporation

Report Structure:

1. Research Scope & Methodology

2. Executive Summary

3. Market Outlook

4. Global Hepatitis Drugs Market Size and Forecast (2011 - 2020)

5. Global Hepatitis Drugs Market Breakdown by Type

6. Global Hepatitis Drugs Market Breakdown by Geography

7. Pipeline Drugs for Hepatitis

8. Drug Approval Process in the .S. and EU

9. Competitive Positioning and Market Share Analysis

10. Company Profiles and Strategic Developments

11. Appendix

For more information visit http://www.researchandmarkets.com/research/gk9j9x/global_hepatitis

View source version on businesswire.com: http://www.businesswire.com/news/home/20160208005715/en/

[ Back To TMCnet.com's Homepage ]